Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Cretostimogene in Non-muscle invasive bladder cancer, Cancer. The expected timing is based on the latest available company guidance and may change.
PIVOT-006 trial. 2/27/24- First patient dosed. 9/3/25- Completed enrollment. 11/14/25:- PIVOT-006 enrollment completion reaffirmed; randomized Phase 3 intermediate-risk NMIBC trial completed enrollment about ten months early. 01/09/26:- Topline data in H1 2026, nearly one year earlier. 02/27/26:- PIVOT-006 Phase 3 randomized trial topline data reaffirmed for first half 2026, with results expected in coming months. 05/08/26:- Phase 3 PIVOT-006 topline data reaffirmed for first half 2026, with readout expected in coming months. 08/06/26:- PIVOT-006 target events mostly accrued; Phase 3 topline data expected near-term in 2026.
Verification
Confirm timing and program details against the company announcement or filing.